• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)

PRODUCT FILTERS

REGION

1,142
109
76
71
69

COUNTRY

70
22
16
10
9

CATEGORIES

  • 575
  • 121
  • 550
  • 75
  • 526
  • 43
  • 505
  • 18
  • 18
  • 23

PRICE

1,047
1,237
1,988
3,000

PUBLISHED

26
211
644
3,000

PRODUCT TYPE

2,427
494
69
7
1
1
1

Oncology

The American Cancer Society forecasts that 1,638,910 new cancer cases will occur in the United States in 2012. As cancer rates worldwide are increasing, the oncological sector of the pharmaceutical industry is growing fast and it will continue to provide business opportunities in the next years. However, cancer trials are some of the most complex, time consuming and expensive across all therapeutic areas. What are the new paths to success in this lucrative but challenging market?

Find out the answer in the reports, books, and subscriptions listed under Research and Markets’ Oncology category. Our top-quality publications from industry experts cover every aspect of cancer drug therapy, with a focus on: Lung Cancer, Breast Cancer, Prostate Cancer, Leukaemia, Lymphoma, Ovarian Cancer, Colon Cancer, Cervical Cancer, Brain Cancer and Bladder Cancer. So read on for the latest clinical trials, pipeline reviews, industry news, and commercial opportunities.

Key players featured in our publications include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis, Wyeth, and many more. Show Less
Read more

PRODUCT TITLE

Soft Tissue Sarcoma - Pipeline Review, H2 2013

Soft Tissue Sarcoma - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Soft Tissue Sarcoma - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This...

October 2013
FROM

Uterine Cancer - Pipeline Review, H2 2013

Uterine Cancer - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Uterine Cancer - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides...

October 2013
FROM

Burkitt Lymphoma - Pipeline Review, H2 2013

Burkitt Lymphoma - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Burkitt Lymphoma - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report...

October 2013
FROM

Waldenstrom Macroglobulinemia - Pipeline Review, H2 2013

Waldenstrom Macroglobulinemia - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Waldenstrom Macroglobulinemia - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic...

October 2013
FROM

Gastrointestinal Tumor - Pipeline Review, H2 2013

Gastrointestinal Tumor - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Gastrointestinal Tumor - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline....

October 2013
FROM

Metastatic Hepatocellular Carcinoma (HCC) - Pipeline Review, H2 2013

Metastatic Hepatocellular Carcinoma (HCC) - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Metastatic Hepatocellular Carcinoma (HCC) - Pipeline Review, H2 2013', provides an overview of...

October 2013
FROM

Metastatic Ovarian Cancer - Pipeline Review, H2 2013

Metastatic Ovarian Cancer - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Metastatic Ovarian Cancer - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline....

October 2013
FROM

Ovarian Cancer - Pipeline Review, H2 2013

Ovarian Cancer - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Ovarian Cancer - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides...

October 2013
FROM

T-Cell Lymphomas - Pipeline Review, H2 2013

T-Cell Lymphomas - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'T-Cell Lymphomas - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report...

October 2013
FROM

Osteosarcoma - Pipeline Review, H2 2013

Osteosarcoma - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Osteosarcoma - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides...

October 2013
FROM

Neuroendocrine Tumors - Pipeline Review, H2 2013

Neuroendocrine Tumors - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Neuroendocrine Tumors - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline....

October 2013
FROM

Reimbursement for IVD Tests

What is the procedure, for establishing reimbursement for an IVD test product?  What companies have been successful and how?  What changes will IVD makers face in the near-term.  This Kalorama Information...

October 2013
FROM
Quest for the Cure Quest for the Cure - Product Thumbnail Image

Quest for the Cure

This original fourteen chapter book is a brief, slightly autobiographic tale of medical oncologists, surgeons, radiation oncologists, and breast cancer patients in a well-established cancer center in...

October 2013

Mammography Equipment Market to 2019 - Growth Driven by Technical Advances in Digital Radiography that Enhance Workflow and Improve Breast Cancer Detection

“Mammography Equipment Market to 2019 - Growth Driven by Technical Advances in Digital Radiography that Enhance Workflow and Improve Breast Cancer Detection” looks at the market, competitive landscape,...

October 2013
FROM

Waldenstrom Macroglobulinemia Global Clinical Trials Review, H2, 2013

Waldenstrom Macroglobulinemia Global Clinical Trials Review, H2, 2013 Summary Our clinical trial report, “Waldenstrom Macroglobulinemia Global Clinical Trials Review, H2, 2013" provides data on the...

October 2013
FROM
Colorectal Cancer - KOL Insight Module Colorectal Cancer - KOL Insight Module - Product Thumbnail Image

Colorectal Cancer - KOL Insight Module

The global market for colorectal cancer (CRC) drugs is undergoing a fundamental shift due to wider generic competition in cytotoxics and increasing adoption of anti-EGFR products as first line therapies...

October 2013
FROM

Europe Breast Cancer Drug Pipeline Analysis

The pharmaceutical companies have recently been focusing increasingly on women's health Among the diseases specific to women, breast cancer has become one of the leading causes of death for the women...

October 2013
FROM

Orphan Drugs for Cancer Pipeline Analysis

A huge market opportunity is offered by small patient population which suffers from rare or orphan diseases Among the category of new orphan drugs, Oncology account for the largest disease group in...

October 2013
FROM

US Prostate Cancer Drug Pipeline Analysis

Prostate cancer has emerged as one of the most commonly diagnosed cancer among men in the US According to the American Cancer Society, there were close to 242,000 new cases of prostate cancer in the...

October 2013
FROM

US Breast Cancer Drug Pipeline Analysis

The pharmaceutical companies have recently been focusing increasingly on women's health Among the diseases specific to women, breast cancer has become one of the leading causes of death for the women...

October 2013
FROM
Loading Indicator

Our Clients

Our clients' logos